**PHARMACOMETABOLIC BIOMARKER RESULTS**

**Analysis of fresh blood by FACS (subset of subjects)**
- Eftilagimod alpha (efti) is a soluble LAG-3 protein targeting a subset of MBC class II molecules, and thus likely inducing an activating signal on CD8+ T cells (APC) and CD3 T cell activation (Fig. 9).
- This activation of the dendritic cell network resulted in CD4+ T cell recruitment may lead to emergence of a more immune-competent population in combination with paclitaxel as observed in the baseline analysis (Figs. 5, 6).
- The modelling strategy used backward selection with factors being excluded if p<0.15, and CDK 4/6 was further excluded from the model (Table 1).

**RESULTS**
- Samples were taken prior to the next efti/placebo administration visit. All patients remained on investigator's treatment regime for the duration of the study.
- Mean absolute gains ranged from 4.2 (luminal B) to 19.6 (low monocytes) months.
- Fold change mean sorting analysis for absolute lymphocyte count (ALC) was measured locally at clinical sites according to the definition (Fig. 10).
- Mean absolute gains ranged from 10.0% (luminal B) to 19.4% (no prior taxanes).
- In the multivariate analysis for OS, tumor responses in the efti group were observed (Fig. 11).
- In the multivariate analysis for OS, this will be considered for patient population selection for future studies (e.g. phase III).